The latest report by IMARC Group, titled “Biologics Market Report by Source (Microbial, Mammalian, and Others), Product (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense, RNAi and Molecular Therapy, and Others), Disease (Oncology, Immunological Disorders, Cardiovascular Disorders, Hematological Disorders, and Others), Manufacturing (Outsourced, In-House), and Region 2025-2033,” offers a comprehensive analysis of the biologics market outlook. The report also includes competitor and regional analysis, along with a breakdown of segments within the industry.
The global biologics market size reached USD 377.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 769.7 Billion by 2033, exhibiting a growth rate (CAGR) of 7.38% during 2025-2033.
Request Free Sample Report: https://www.imarcgroup.com/biologics-market/requestsample
Biologics Market Trends:
The global market is primarily driven by the increasing prevalence of chronic diseases, such as cancer and autoimmune disorders, requiring targeted and effective treatments. In accordance with this, the growing demand for personalized medicine, with biologics being a central component in tailored therapeutic approaches, is also contributing to market growth. Furthermore, continual advancements in biotechnology and genetic engineering enabling the development of more innovative and potent biologic drugs, is fueling the market expansion.
Similarly, the rising investment in research and development (R&D) by pharmaceutical companies is further accelerating the market demand. Besides this, regulatory support for biologic drug approval, coupled with fast-track designations for breakthrough therapies, is making market entry easier for new treatments. Moreover, the rapid expansion of biosimilars, providing more affordable options and accessibility, is another key market driver.
Biologics Market Scope and Growth Analysis:
The scope of the market is vast, with significant potential for growth across multiple therapeutic areas, including oncology, immunology, and neurology. As biologic drugs continue to demonstrate high efficacy and specificity, their adoption in healthcare systems globally is expected to increase. The ongoing advancements in biomanufacturing technologies, such as cell culture systems and bioprocessing techniques, are improving production efficiency and reducing costs, further supporting expansion in the market.
As per market analysis, the growing focus on biosimilars, particularly in cost-sensitive markets, is creating new growth avenues in the market. Additionally, the rapid integration of artificial intelligence (AI) and data analytics in research is enhancing drug development and precision medicine initiatives. Moreover, the increasing awareness of biologics' potential in treating rare diseases is driving demand in niche markets. As demand for advanced therapies continues to rise, the market scope is expected to experience sustained growth, fueled by innovation, and increasing global healthcare needs.
View Full Report with TOC & List of Figure: https://www.imarcgroup.com/biologics-market
Biologics Market Segmentation:
Breakup by Source:
- Microbial
- Mammalian
- Others
Microbial accounts for the majority of the biologics market share.
Breakup by Product:
- Monoclonal Antibodies
- Vaccines
- Recombinant Proteins
- Antisense, RNAi and Molecular Therapy
- Others
Monoclonal antibodies represent the largest market segment.
Breakup by Disease:
- Oncology
- Immunological Disorders
- Cardiovascular Disorders
- Hematological Disorders
- Others
Oncology accounts for the majority of the market share.
Breakup by Manufacturing:
- Outsourced
- In-House
In-house represents the largest market segment.
Breakup by Region:
- North America (USA, Canada)
- Europe (Germany, France, UK, Italy, Spain, Russia, others)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, others)
- Middle East/Africa
- Latin America (Brazil, Mexico, others)
Top Biologics Market Leaders:
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca plc
- Hoffmann-La Roche Ltd
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Sanofi
About US:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
